

Abstract

(5.7%) in HTN-2. Prevalence of LVH increased with higher SBP with 96/493

(19.5%) in NT, 80/214 (37.4%) in E-BP, 32/99 (32.3%) in HTN-1, and 20/49 (40.8%) in HTN-

60 **Introduction**

81

Methods

Study Population

- We performed a retrospective analysis of an echocardiogram database and the
- Electronic Medical Record of adolescent patients aged 13-17 years with biventricular CHD

(excluding those patients with single ventricular or functionally single ventricular lesions such as

hypoplastic left heart syndrome, tricuspid atresia, and pulmonary atresia with intact ventricular

septum, or others who have required single-ventricle palliation) from 2012-2019 at Nationwide

- Children's Hospital. We chose to study this age distribution as the blood pressure cutoffs in this
- 90 population directly correlate with those in the adult population¹⁷ in which adverse CV outcomes
- are described. Only patients with documented blood pressure, height, weight, body mass index
- (BMI), and echocardiographic data for LVM calculation at the time of their most recent
- echocardiogram were included.
-

Echocardiogram Parameters and LVM

 For the purposes of this study, the echocardiographic measurements were measured off M- Mode, a standard for LV quantification in our lab during this timeframe. Demographic data and echocardiographic variables for assessment of LVH are included in **Table 1**. Measurements of the interventricular septum (IVSd) and left ventricular posterior wall (LVPWd) were taken at end-diastole. Left ventricular dimensions were taken at end-diastole (LVEDD) and end-systole (LVESD). LVM was determined via the formula proposed by Devereux et al: 0.8x $(1.04x[(IVS+LVID+PWT)^3-LVID^3]+0.6 \text{ grams}^{18}.$

103 LVM was then indexed to body height to the power of 2.7 (LVMI-ht^{2.7}=LVM/height^{2.7}) to adjust 104 for differences in body size^{18, 19}. LV function was assessed by left ventricular shortening fraction 105 (LVSF).

106

107 *Blood Pressure Definitions and Categories*

108 Patients were stratified by blood pressure category into normotensive (NT, SBP<120 mmHg),

109 elevated blood pressure (E-BP, 120≤SBP<130 mmHg), stage 1 HTN (HTN-1, 130≤SBP<140

110 mmHg), and stage 2 HTN (HTN-2, SBP≥140 mmHg) per the 2017 Clinical Practice Guideline

111 (CPG) for Screening and Management of Blood Pressure in Children and Adolescents¹⁷ utilizing

112 the automated blood pressure taken at the time of their most recent echocardiogram. The

113 prevalence of LVH was reported in each group using the pediatric cutoff for LVH of LVMI-ht^{2.7} ≥

114 $\,$ 38.6 g/ht^{2.7} which corresponds to the 95th percentile for LVMI-ht^{2.7} in children and increases

115 the sensitivity for detecting LVH before it reaches a level associated with CV events in

116 adulthood^{15, 20}. Results were also compared to the 2017 CPG recommendation of LVMI-ht^{2.7} ≥

117 51g/ht^{2.7} for LVH, which is the adult cutoff associated with increased risk for cardiovascular

118 events 21 but which is far above the 95th percentile values in pediatrics 17 .

119

120 *BMI stratification*

 BMI percentiles were obtained from the Centers for Disease Control and Prevention growth 122 charts. BMI z-scores were calculated by $BMIz=(BMI/M)L-1/(L*S)$, where L, M, and S are reference values from the growth chart for the corresponding child age and sex. BMI percentiles were calculated from z-scores based on the normal distribution. Subjects were

Statistical analysis

 Data were summarized using frequency (percentage) for categorical variables, mean (standard deviation, SD) for continuous symmetric variables, and median (interquartile range, IQR) for continuous skewed variables. Data were quality checked and distributions were visualized using bar and violin plots. For model stability, race groups were aggregated into white, black, or other (includes American Indian, Asian, Hispanic, Native American, Pacific Islander, biracial, and other). Prevalence of LVH among each blood pressure group was calculated. Among adolescents that met pediatric LVH criteria, the percentage also meeting the adult LVH criteria was calculated. Pairwise comparisons were performed for the echocardiogram parameters between each blood pressure category and adjusted for multiple comparisons utilizing the Bonferroni correction. Univariable linear regression models were constructed for continuous 139 outcomes LVMI-ht^{2.7}, LVEDD, LVESD, LVPWd, IVSd, LVSF, and LVEF. Predictor variables included age, sex, race, continuous SBP, and BMI percentile. Multivariable linear regression models were fit for each outcome with the same independent variables, using complete cases without missing predictors. The interaction term between SBP and BMI percentile was also assessed and removed from the model if not significantly associated with the outcome. P-values < 0.05 were considered statistically significant. All statistical analyses were performed in R version 4.0 (R Core Team, Vienna, Austria).

Results

Patient Characteristics

- 149 A total of 855 patients met the inclusion criteria (56.7% male) with mean (SD) age 15.5 ± 1.5
- years (range 13.0 to 17.9 years). Patient characteristics can be found in **Table 1**. The race of
- patients was predominantly White (79.9%). BMI, BMI percentile, and body surface area (BSA)
- trended higher in the abnormal blood pressure groups. Over half of patients were NT (57.7%),
- with 25%, 11.6% and 5.7% meeting criteria for E-BP, HTN-1, and HTN-2, respectively.
-

Echocardiogram Parameters

- Those in the E-BP and HTN-1 groups had higher LVEDD values compared to NT (**Table**
- **2).** Patients with abnormal BP had thicker LVPWd and IVSd compared to NT subjects. LVMI-ht^{2.7}
- increased across blood pressure categories and was significantly higher in the abnormal blood
- pressure groups compared to NT. One-third of patients in the HTN-1 and 41% of patients in the
- HTN-2 category met criteria for LVH. Of the youths with LVH, one-fifth (21.5%) met the adult
- 161 criteria for LVH with LVMI-ht^{2.7} \geq 51g/ht^{2.7}. Ejection fraction was preserved and consistent
- across blood pressure categories.
-

Univariable and Multivariable Linear Regression Models

Univariable linear regression demonstrated age, male sex, BMI percentile, and SBP were

- significantly associated with LVH **(Table 3)**. After adjustment in a multivariable linear regression,
- 167 age, male sex, and BMI percentile remained significant predictors of LVMI-ht^{2.7} while SBP no
- longer correlated **(Table 4).** In a subgroup analysis of patients with normal BMI, SBP was an

169 independent predictor of LVMI-ht^{2.7} (p=0.011) on univariable analysis, but lost significance in the adjusted model.

Discussion

HTN

 There is a paucity of data related to HTN and LVH in the adolescent congenital heart disease population. We found that in our large cohort of adolescents with biventricular CHD, over 40% had abnormal blood pressure. LVM was linearly associated with elevated blood pressure such that only 20% of those with normal blood pressure had LVH by echocardiography compared to 35% of those with HTN. The rates of abnormal blood pressure in our group were higher than 179 those previously reported for youth in the general population²²⁻²⁶, which may reflect the impact of the underlying CHD on vascular tone. Indeed, Mivelaz et al demonstrated elevated aortic 181 stiffness in a similar cohort of adolescents with biventricular CHD 27 , which is a vascular marker 182 linked to future cardiovascular morbidity and mortality²⁸. This is not surprising given that patients with CHD often have several risk factors for HTN including chronic renal insufficiency as well as changes in arterial wall architecture that places them at higher risk of abnormal blood 185 pressure^{29, 30}. High blood pressure did not remain a significant risk factor for LVH in multivariable regression analysis. We suspect this may be due to a longitudinal effect of blood pressure on LVM that may not be seen until the adult years. Nonetheless, we know that 188 hypertensive youths are prone to becoming adults with HTN $31-33$ and that identification of abnormal blood pressures in the formative years may play an important prognostic role.

- 190 Perhaps annual ambulatory blood pressure monitoring in adolescents with CHD would be best
- 191 practice to screen for those already experiencing elevated blood pressures.
- 192
- 193 *LVH*

194 LVMI-ht^{2.7} appeared to be higher in those with higher BP on univariate analysis consistent with 195 previous findings in children and adolescents without CHD³⁴. One-fifth of patients with LVH met 196 adult criteria which is higher than levels previously reported for hypertensive young patients 197 without CHD¹⁶, suggesting a compounding effect of underlying CHD on the development of 198 LVH. Age, male sex, BMI percentile, and blood pressure were significantly associated with LVMI-199 ht^{2.7} using univariable analysis. After adjusting for variables in a multilinear regression model, 200 age, male sex, and BMI percentile remained significant predictors of LVMI-ht^{2.7} while SBP lost 201 its significance, similar to previous findings in adults by de Simone et al. 18 . However, data from 202 the SHIP AHOY study group have demonstrated SBP to be a significant determinant of LVMI-203 $\frac{h^2}{2}$ in healthy adolescents after adjusting for covariates¹⁵. Their cohort age range skewed older 204 than the current data set, suggesting a longitudinal effect of SBP on LVMI-ht^{2.7} which may have 205 risen to significance on multivariate analysis in our cohort if given more time.

206

207 *BMI*

208 The association between obesity, HTN, and LVH in the general pediatric population is well-209 documented³⁵⁻³⁸. Children without CHD with overweight or obesity and HTN were found to 210 have higher LVM indices at baseline and longitudinally compared to those of healthy weight 211 who were hypertensive³⁹. Our study of children with CHD mirrors these findings with one in five

212 patients having obesity and BMI percentile being significantly associated with LVMI-ht^{2.7}. This is important because children with CHD can be at higher risk for future CV events compared to 214 non-CHD children⁴⁰ so the presence of obesity and early echocardiographic changes may further compound future risk in these patients. Weight continues to prove itself to be a crucial factor in the development of LVH. Similar to our findings, in a cohort of 160 pediatric patients from the Bogalusa Heart study, weight remained the only significant predictor for LVM in multivariate analysis after controlling for age, sex, and 220 SBP ⁴¹. Burke et al. found that adults in the MESA study who were obese had a two-fold 221 increased risk of having LVM exceeding the $80th$ percentile compared to those with a normal body size after adjustment for traditional risk factors, making body size a potentially modifiable 223 risk factor for subclinical CV disease.

225 Our study was novel in having a large cohort of patients inclusive of a large spectrum of biventricular CHD. We also utilized the most up to date guidelines for characterizing HTN in the 227 adolescent population¹⁷ which is felt to capture more accurately those with abnormal blood pressures. Prior studies on HTN and LV geometry changes in CHD have focused primarily on 229 coarctation of the aorta and its associated long-term outcomes^{43, 44}. While our study included patients with left ventricular outflow tract (LVOT) obstructions, the majority of documented LVOT gradients on the echocardiograms used for this study demonstrated no or mild residual pressure gradient, indicating that a residual obstruction is less likely responsible for any observed increase in LVM. This study broadens our understanding of the impact of HTN and

 overweight/obesity on children with CHD. Our study highlights the need for early detection of abnormal BP and obesity in patients with CHD to prevent progression of LVH to levels known to be associated with hard CV events. Knowledge of the risk for LVH in this age group becomes increasingly important considering findings that elevated LVM can be found at blood pressures 238 below the current definition of pediatric HTN ¹⁵. Furthermore, elevated blood pressure has 239 been associated with systolic and diastolic dysfunction^{45, 46} which may already be compromised 240 by the patient's CHD. With the knowledge of early abnormal blood pressure and evidence of increased LVM in overweight and obese patients with CHD, it becomes vital to screen patients and to be vigilant about providing anticipatory guidance and considering pharmacological intervention in patients who meet criteria. This is especially important in light of evidence that 244 regression in LVM leads to lesser risk of CV disease ⁸. Targeted diet and lifestyle 245 recommendations such as the Dietary Approaches to Stop Hypertension (DASH) 17 and the Cardiovascular Health Integrated Lifestyle Diet (CHILD) recommended by the American 247 Academy of Pediatrics (AAP)⁴⁷ should be stressed particularly in this patient population. 248 Physical activity recommendations should also be emphasized ⁴⁸ depending on appropriate activity clearance by heart lesion. Current pediatric hypertension guidelines recommend yearly ambulatory blood pressure monitor (ABPM) placement in patients with repaired aortic 251 coarctation ; however, ABPM can also be useful in screening other CHD patients for hypertension.

Limitations

255 While our study is one of the largest to evaluate BP and LVMI-ht^{2.7} amongst the pediatric CHD population, there are several inherent limitations that should be noted. Our study is a single center retrospective cohort study which limits the ability to determine causation for increased LVM. We believe that with our large sample size, which encompasses all types of biventricular CHD, we avoided selection bias that can accompany some retrospective studies. To that end, we did not stratify by types of CHD and it is possible that our population potentially includes a larger percentage of patients with left ventricular outflow tract obstructive lesions which are known to be risk factors for LVH. This will need to be further elucidated in future studies. Given the descriptive nature of our work, whether patients were identified as hypertensive or if they were being actively treated for HTN was not investigated. Additionally, single time-point blood pressures were utilized for our analysis. Serial blood pressure evaluation and incorporation of ambulatory blood pressure monitoring data would further enhance our understanding of the true prevalence of HTN in this cohort and provide insight into the timing of development of end-organ damage. Future studies should be aimed at longitudinal changes in blood pressure and LVH and the impact of pharmacological intervention and social determinants on HTN, obesity, and evidence of cardiac dysfunction in the pediatric CHD population.

Acknowledgements

Sources of Funding: None

Disclosures: No authors have relevant disclosures.

References

 1. Global, regional, and national burden of congenital heart disease, 1990-2017: A systematic analysis for the global burden of disease study 2017. *Lancet Child Adolesc Health*. 2020;4:185-200 2. van der Linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJ, et al. Birth prevalence of congenital heart disease worldwide: A systematic review and meta- analysis. *J Am Coll Cardiol*. 2011;58:2241-2247 3. Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N, Kaouache M. Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. *Circulation*. 2014;130:749-756 4. Moons P, Van Deyk K, Dedroog D, Troost E, Budts W. Prevalence of cardiovascular risk factors in adults with congenital heart disease. *Eur J Cardiovasc Prev Rehabil*. 2006;13:612-616 5. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the framingham heart study. *N Engl J Med*. 1990;322:1561-1566 6. Bluemke DA, Kronmal RA, Lima JA, Liu K, Olson J, Burke GL, et al. The relationship of left ventricular mass and geometry to incident cardiovascular events: The mesa (multi- ethnic study of atherosclerosis) study. *J Am Coll Cardiol*. 2008;52:2148-2155 7. Kawel-Boehm N, Kronmal R, Eng J, Folsom A, Burke G, Carr JJ, et al. Left ventricular mass at mri and long-term risk of cardiovascular events: The multi-ethnic study of atherosclerosis (mesa). *Radiology*. 2019;293:107-114 8. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. *Circulation*. 1998;97:48-54 9. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. *Hypertension*. 2000;35:580-586 10. Verdecchia P, Carini G, Circo A, Dovellini E, Giovannini E, Lombardo M, et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: The mavi study. *J Am Coll Cardiol*. 2001;38:1829-1835 11. Gardin JM, McClelland R, Kitzman D, Lima JA, Bommer W, Klopfenstein HS, et al. M- mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the cardiovascular health study). *Am J Cardiol*. 2001;87:1051-1057 12. Verma A, Meris A, Skali H, Ghali JK, Arnold JM, Bourgoun M, et al. Prognostic implications of left ventricular mass and geometry following myocardial infarction: The valiant (valsartan in acute myocardial infarction) echocardiographic study. *JACC Cardiovasc Imaging*. 2008;1:582-591 13. Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, et al. Increased left ventricular mass is a risk factor for the development of a depressed left

 28. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all- cause mortality with arterial stiffness: A systematic review and meta-analysis. *Journal of the American College of Cardiology*. 2010;55:1318-1327 29. Morgan CJ, Zappitelli M, Robertson CMT, Alton GY, Sauve RS, Joffe AR, et al. Risk factors for and outcomes of acute kidney injury in neonates undergoing complex cardiac surgery. *The Journal of Pediatrics*. 2013;162:120-127.e121 30. Roche SL, Silversides CK. Hypertension, obesity, and coronary artery disease in the survivors of congenital heart disease. *Can J Cardiol*. 2013;29:841-848 31. Tirosh A, Afek A, Rudich A, Percik R, Gordon B, Ayalon N, et al. Progression of normotensive adolescents to hypertensive adults: A study of 26,980 teenagers. *Hypertension*. 2010;56:203-209 32. Sun SS, Grave GD, Siervogel RM, Pickoff AA, Arslanian SS, Daniels SR. Systolic blood pressure in childhood predicts hypertension and metabolic syndrome later in life. *Pediatrics*. 2007;119:237-246 33. Bao W, Threefoot SA, Srinivasan SR, Berenson GS. Essential hypertension predicted by tracking of elevated blood pressure from childhood to adulthood: The bogalusa heart study. *Am J Hypertens*. 1995;8:657-665 34. Stabouli S, Kotsis V, Rizos Z, Toumanidis S, Karagianni C, Constantopoulos A, et al. Left ventricular mass in normotensive, prehypertensive and hypertensive children and adolescents. *Pediatr Nephrol*. 2009;24:1545-1551 35. Lurbe E, Alvarez V, Liao Y, Tacons J, Cooper R, Cremades B, et al. The impact of obesity and body fat distribution on ambulatory blood pressure in children and adolescents. *Am J Hypertens*. 1998;11:418-424 36. Movahed M-R, Bates S, Strootman D, Sattur S. Obesity in adolescence is associated with left ventricular hypertrophy and hypertension. *Echocardiography*. 2011;28:150-153 37. Sivanandam S, Sinaiko AR, Jacobs DR, Steffen L, Moran A, Steinberger J. Relation of increase in adiposity to increase in left ventricular mass from childhood to young adulthood. *The American Journal of Cardiology*. 2006;98:411-415 38. Mensah GA, Treiber FA, Kapuku GK, Davis H, Barnes VA, Strong WB. Patterns of body fat deposition in youth and their relation to left ventricular markers of adverse cardiovascular prognosis. *The American journal of cardiology*. 1999;84:583-588 39. Brady TM, Appel LJ, Holmes KW, Fivush B, Miller ER, 3rd. Association between adiposity and left ventricular mass in children with hypertension. *Journal of clinical hypertension (Greenwich, Conn.)*. 2016;18:625-633 40. Wang T, Chen L, Yang T, Huang P, Wang L, Zhao L, et al. Congenital heart disease and risk of cardiovascular disease: A meta-analysis of cohort studies. *J Am Heart Assoc*. 2019;8:e012030 41. Urbina EM, Gidding SS, Bao W, Pickoff AS, Berdusis K, Berenson GS. Effect of body size, ponderosity, and blood pressure on left ventricular growth in children and young adults in the bogalusa heart study. *Circulation*. 1995;91:2400-2406 42. Burke GL, Bertoni AG, Shea S, Tracy R, Watson KE, Blumenthal RS, et al. The impact of obesity on cardiovascular disease risk factors and subclinical vascular disease: The multi-ethnic study of atherosclerosis. *Arch Intern Med*. 2008;168:928-935

433 **Tables**

434

435 Table 1. Subject characteristics

436 *HTN, hypertension; BMI, body mass index; SD, standard deviation; IQR, interquartile range

437 Table 2. Echocardiogram Parameters

¹ Medians (IQR), ²Adjusted pairwise p-value <0.05 when NT compared to E-BP, ³Adjusted pairwise p-value <0.05 when NT compared to HTN-1, ⁴Adjusted pairwise p-value <0.05 when NT compared to HTN-2; NS, Non-significant pairwise p-value when NT compared to BP categories

438 *HTN, hypertension; BMI, body mass index; LVEDD, left ventricular end-diastolic dimension;

439 LVESD, left ventricular end-systolic dimension; LVPWd, left ventricular posterior wall thickness

440 in diastole; IVSd, interventricular septal thickness in diastole; LVMI Ht2.7; left ventricular mass

441 indexed to height to the power of 2.7; LVSF, left ventricular shortening fraction; LVEF, left

442 ventricular ejection fraction; SD, standard deviation; IQR, interquartile range. Values given as

443 medians and IQR.

444 Table 3. Univariable linear regression model for LVMI-ht^{2.7}

446

447

448

449

450

452 Table 4. Multivariable linear regression model for LVMI-ht^{2.7}

^{*}LVMI-ht^{2.7}, left ventricular mass indexed to height to the power of 2.7; BMI, body mass index